Compare AXSM & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXSM | TPG |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.9B |
| IPO Year | 2015 | 2022 |
| Metric | AXSM | TPG |
|---|---|---|
| Price | $176.97 | $66.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | ★ $183.10 | $66.45 |
| AVG Volume (30 Days) | 773.1K | ★ 1.3M |
| Earning Date | 02-17-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.10 |
| Revenue | $561,263,000.00 | ★ $4,255,344,000.00 |
| Revenue This Year | $66.40 | N/A |
| Revenue Next Year | $56.13 | $31.12 |
| P/E Ratio | ★ N/A | $677.41 |
| Revenue Growth | ★ 65.83 | 24.91 |
| 52 Week Low | $80.98 | $37.52 |
| 52 Week High | $184.40 | $70.38 |
| Indicator | AXSM | TPG |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 55.34 |
| Support Level | $165.75 | $65.11 |
| Resistance Level | $184.40 | $67.50 |
| Average True Range (ATR) | 7.05 | 1.72 |
| MACD | 1.08 | -0.19 |
| Stochastic Oscillator | 79.11 | 35.81 |
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.